Akiko Sarashina

926 total citations
35 papers, 785 citations indexed

About

Akiko Sarashina is a scholar working on Oncology, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Akiko Sarashina has authored 35 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Endocrinology, Diabetes and Metabolism and 9 papers in Molecular Biology. Recurrent topics in Akiko Sarashina's work include Diabetes Treatment and Management (12 papers), Diabetes Management and Research (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Akiko Sarashina is often cited by papers focused on Diabetes Treatment and Management (12 papers), Diabetes Management and Research (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Akiko Sarashina collaborates with scholars based in Japan, Germany and United States. Akiko Sarashina's co-authors include Klaus A. Dugi, Hans J. Woerle, Atsushi Taniguchi, Yoshiharu Horie, Naoyuki Hayashi, Norio Yamamura, Kazuki Koiwai, Hirotaka Watada, Leo Seman and Shogo Sesoko and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Akiko Sarashina

35 papers receiving 759 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Akiko Sarashina Japan	16	415	273	270	204	176	35	785
Charles Carmeci United States	8	324 0.8×	265 1.0×	121 0.4×	341 1.7×	88 0.5×	10	896
E. Blind Germany	15	479 1.2×	433 1.6×	393 1.5×	239 1.2×	64 0.4×	48	1.1k
Holger Huisman Germany	10	384 0.9×	325 1.2×	348 1.3×	184 0.9×	212 1.2×	20	1.1k
Dirk Trommeshauser Germany	14	156 0.4×	254 0.9×	284 1.1×	78 0.4×	74 0.4×	21	713
Q. Shao China	14	595 1.4×	409 1.5×	207 0.8×	249 1.2×	49 0.3×	31	914
Nobuyuki Yasuda Japan	19	351 0.8×	332 1.2×	358 1.3×	236 1.2×	44 0.3×	43	1.1k
Edward J. Gonzalez United States	9	306 0.7×	113 0.4×	393 1.5×	168 0.8×	136 0.8×	9	661
Jean‐François Desjardins Canada	15	198 0.5×	255 0.9×	57 0.2×	154 0.8×	89 0.5×	34	617
Siyer Roohani Germany	11	234 0.6×	176 0.6×	52 0.2×	147 0.7×	74 0.4×	37	614

Countries citing papers authored by Akiko Sarashina

Since Specialization

Citations

This map shows the geographic impact of Akiko Sarashina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akiko Sarashina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akiko Sarashina more than expected).

Fields of papers citing papers by Akiko Sarashina

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akiko Sarashina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akiko Sarashina. The network helps show where Akiko Sarashina may publish in the future.

Co-authorship network of co-authors of Akiko Sarashina

This figure shows the co-authorship network connecting the top 25 collaborators of Akiko Sarashina. A scholar is included among the top collaborators of Akiko Sarashina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akiko Sarashina. Akiko Sarashina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yamamoto, Noboru, Takafumi Koyama, Toshio Shimizu, et al.. (2023). Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 91(6). 469–480. 6 indexed citations

Doi, Toshihiko, Kenjiro Aogi, Motohiro Tamiya, et al.. (2023). MO11-1 Phase I dose-finding study of the SIRPα inhibitor BI 765063 as monotherapy in Japanese patients with advanced cancer. Annals of Oncology. 34. S1403–S1403. 1 indexed citations

Sarashina, Akiko, et al.. (2020). Physiologically Based Pharmacokinetic Model of the DPP-4 Inhibitor Linagliptin to Describe its Nonlinear Pharmacokinetics in Humans. Journal of Pharmaceutical Sciences. 109(7). 2336–2344. 5 indexed citations

Matsumura, Naoya, Shun Hayashi, Akiko Sarashina, et al.. (2019). Prediction Characteristics of Oral Absorption Simulation Software Evaluated Using Structurally Diverse Low-Solubility Drugs. Journal of Pharmaceutical Sciences. 109(3). 1403–1416. 19 indexed citations

Shimada, Akira, Toshiaki Hanafusa, Atsutaka Yasui, et al.. (2018). Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial. Diabetes Obesity and Metabolism. 20(9). 2190–2199. 33 indexed citations

Yamamoto, Noboru, Hirotsugu Kenmotsu, Kōichi Goto, et al.. (2018). An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy. Cancer Chemotherapy and Pharmacology. 82(4). 685–694. 3 indexed citations

Mukai, Hirofumi, Norikazu Masuda, Hiroshi Ishiguro, et al.. (2015). Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. Cancer Chemotherapy and Pharmacology. 76(4). 739–750. 11 indexed citations

Okamoto, Isamu, Masaki Miyazaki, Masayuki Takeda, et al.. (2014). Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 10(2). 346–352. 30 indexed citations

Sarashina, Akiko, Kohjiro Ueki, T. Sasaki, et al.. (2014). Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, and Safety of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Japanese Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics. 36(11). 1606–1615. 26 indexed citations

10.

Kanada, Shigeto, Kazuki Koiwai, Atsushi Taniguchi, et al.. (2013). Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation. 4(6). 613–617. 41 indexed citations

11.

Masuda, Norikazu, Ayako Mitsuma, T. Shibata, et al.. (2013). Abstract P4-16-11: Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors including breast cancer. Cancer Research. 73(24_Supplement). P4–16. 1 indexed citations

12.

Sarashina, Akiko, Yasuhiro Tsuda, Christian Friedrich, et al.. (2013). Population Pharmacokinetic/Pharmacodynamic Analysis of the DPP-4 Inhibitor Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus. Journal of Pharmacy & Pharmaceutical Sciences. 16(5). 708–708. 11 indexed citations

13.

Sarashina, Akiko, Kazuki Koiwai, Leo Seman, et al.. (2012). Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects. Drug Metabolism and Pharmacokinetics. 28(3). 213–219. 73 indexed citations

14.

Kawamori, Ryuzo, Nobuya Inagaki, Eiichi Araki, et al.. (2011). Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator‐controlled, double‐blind study. Diabetes Obesity and Metabolism. 14(4). 348–357. 101 indexed citations

15.

Horie, Yoshiharu, Shigeto Kanada, Hirotaka Watada, et al.. (2011). Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients. Clinical Therapeutics. 33(7). 973–989. 42 indexed citations

16.

Okamoto, Isamu, Hiroyasu Kaneda, Taroh Satoh, et al.. (2010). Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 9(10). 2825–2833. 79 indexed citations

17.

Tsuda, Yasuhiro, Norio Yamamura, Akiko Sarashina, et al.. (2010). Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non‐neuropathic bladder. British Journal of Clinical Pharmacology. 70(1). 88–101. 7 indexed citations

18.

Sarashina, Akiko, et al.. (2005). Population pharmacokinetics of epinastine, a histamine H_1 receptor antagonist, in adults and children. The Keio Journal of Medicine. 54(1). 49. 1 indexed citations

19.

Sarashina, Akiko, et al.. (2004). Population pharmacokinetics of epinastine, a histamine H₁ receptor antagonist, in adults and children. British Journal of Clinical Pharmacology. 59(1). 43–53. 15 indexed citations

20.

Yamamura, Norio, et al.. (2004). Pharmacokinetic Comparison of an Angiotensin II Receptor Antagonist, Telmisartan, in Japanese and Western Hypertensive Patients Using Population Pharmacokinetic Method. Drug Metabolism and Pharmacokinetics. 19(1). 15–23. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact